Steve Holmes

USPTO Granted Patents = 26 (Patent Applications = 11)

CIPO Patents = 1 (Patent Applications = 1)

EPO Patents = 7 (Patent Applications = 12)

Average Co-Inventor Count = 5.2

ph-index = 7

Forward Citations = 150(Granted Patents)

Location History:

Great Chishill, GB (2015)
Cambridge, GB (2010 - 2024)

Company Filing History:

Bristol-myers Squibb Compnay

patents

4. 1 out of 41

Bristol Meyers Squibb Company

where one patent can have more than one assignee

Years Active: 2010-2024

Loading Chart...

26 patents (USPTO):Sort by Forward Citations

Abstract keywords

1. 12012452 - Compositions monovalent for CD28 binding and methods of use (2024-06-18),

2. 11773175 - Antibodies, uses and methods (2023-10-03),

3. 11753479 - Nucleic acids encoding anti-OX40L antibodies (2023-09-12),

4. 11680101 - Anti-OPG antibodies (2023-06-20),

5. 11396550 - Methods of treating comprising administering anti-OX40L antibodies (2022-07-26),

6. 10919965 - Compositions monovalent for CD28 binding and methods of use (2021-02-16),

7. 10669342 - Anti-OX40L antibodies and methods of treating graft versus host disease (2020-06-02),

8. 10654935 - Methods of treating SLE with anti-OX40L antibodies (2020-05-19),

9. 10259880 - Anti-LIGHT antibodies (2019-04-16),

10. 9908937 - Compositions monovalent for CD28 binding and methods of use (2018-03-06),

11. 9868790 - Synergistic combinations of OX40L antibodies for the treatment of GvHD (2018-01-16),

12. 9868789 - Synergistic combinations of OX40L antibodies for the treatment of GvHD (2018-01-16),

13. 9629909 - Methods for targeting pulmonary diseases with agents that bind a target in pulmonary tissue (2017-04-25),

14. 9587030 - Anti-hOX40L antibodies, uses, and methods (2017-03-07),

15. 9512229 - Synergistic combinations of OX40L antibodies for the treatment of GVHD (2016-12-06),

Title: **Steve Holmes: Innovator in Biotherapeutics**

Introduction

Steve Holmes is a prominent inventor based in Cambridge, GB, known for his significant contributions to the field of biotherapeutics. With an impressive portfolio of 26 patents, he has played a key role in advancing medical technologies that target critical pathways in immune response.

Latest Patents

Among his latest innovations are patents for "Compositions monovalent for CD28 binding and methods of use." This invention discloses domain antibodies that can monovalently bind to CD28, thereby inhibiting its activity. These antibodies consist of a single immunoglobulin variable domain that antagonizes CD28's functionality without substantially activating it. Furthermore, the patent also covers methods for antagonizing interactions between CD80 and/or CD86 with CD28, presenting potential treatment options for diseases linked to these interactions. Additionally, his work includes patents related to anti-human OX40L antibodies, exploring new medical uses and methodologies.

Career Highlights

Steve has significantly impacted the biotechnology industry through his tenure at Kymab Limited and Domantis Limited, where he contributed to pioneering research and development projects. His efforts have led to innovations that are crucial in therapeutic settings, particularly in immunology.

Collaborations

Throughout his career, Steve has collaborated with distinguished professionals, including Jamie Iain Campbell and Ian Kirby. These partnerships have fostered innovative discussions and developments that have enriched his research initiatives in antibody technology.

Conclusion

Steve Holmes exemplifies the spirit of innovation within the biotech sector, consistently pushing the boundaries of biotherapeutics. His extensive patent portfolio not only highlights his inventive capabilities but also underscores his commitment to improving human health through scientific advancements. His work continues to influence the landscape of immunotherapy, paving the way for novel treatments and therapies.

This text is generated by artificial intelligence and may not be accurate.